---
title: Myeloid-derived suppressor cells in cancer and cancer therapy
date: '2024-01-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38191922/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240109170715&v=2.18.0
source: heidelberg[Affiliation]
description: Anticancer agents continue to dominate the list of newly approved drugs,
  approximately half of which are immunotherapies. This trend illustrates the considerable
  promise of cancer treatments that modulate the immune system. However, the immune
  system is complex and dynamic, and can have both tumour-suppressive and tumour-promoting
  effects. Understanding the full range of immune modulation in cancer is crucial
  to identifying more effective treatment strategies. Myeloid-derived suppressor ...
disable_comments: true
---
Anticancer agents continue to dominate the list of newly approved drugs, approximately half of which are immunotherapies. This trend illustrates the considerable promise of cancer treatments that modulate the immune system. However, the immune system is complex and dynamic, and can have both tumour-suppressive and tumour-promoting effects. Understanding the full range of immune modulation in cancer is crucial to identifying more effective treatment strategies. Myeloid-derived suppressor ...